Robert E. Davis

7.4k total citations · 1 hit paper
129 papers, 4.6k citations indexed

About

Robert E. Davis is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Pharmacology. According to data from OpenAlex, Robert E. Davis has authored 129 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Molecular Biology, 37 papers in Cellular and Molecular Neuroscience and 31 papers in Pharmacology. Recurrent topics in Robert E. Davis's work include Receptor Mechanisms and Signaling (26 papers), Tryptophan and brain disorders (24 papers) and Neuroscience and Neuropharmacology Research (18 papers). Robert E. Davis is often cited by papers focused on Receptor Mechanisms and Signaling (26 papers), Tryptophan and brain disorders (24 papers) and Neuroscience and Neuropharmacology Research (18 papers). Robert E. Davis collaborates with scholars based in United States, Sweden and Germany. Robert E. Davis's co-authors include W. Davis Parker, Scott W. Miller, Russell H. Swerdlow, Janice K. Parks, James P. Bennett, Patricia A. Trimmer, Jason P. Sheehan, Jeremy B. Tuttle, Kimberly E. Vanover and Sharon Mates and has published in prestigious journals such as Circulation, Journal of Neuroscience and American Journal of Psychiatry.

In The Last Decade

Robert E. Davis

125 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Origin and functional consequences of the complex I defect in Parkinson's disease

1996 526 citations Russell H. Swerdlow, Janice K. Parks et al. Annals of Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert E. Davis United States	35	2.4k	1.4k	894	846	702	129	4.6k
Shigetoshi Kuroda Japan	38	1.6k 0.7×	1.5k 1.1×	820 0.9×	896 1.1×	919 1.3×	168	4.4k
Robert Nisticò Italy	43	1.8k 0.8×	1.7k 1.2×	313 0.4×	1.3k 1.5×	476 0.7×	149	4.9k
Carmem Gottfried Brazil	42	1.8k 0.7×	734 0.5×	523 0.6×	764 0.9×	367 0.5×	118	4.5k
Edna Grünblatt Switzerland	39	1.4k 0.6×	1.5k 1.1×	769 0.9×	1.3k 1.5×	920 1.3×	162	5.1k
Henry Sershen United States	43	2.9k 1.2×	3.4k 2.5×	366 0.4×	672 0.8×	460 0.7×	164	5.4k
Sahebarao P. Mahadik United States	39	1.8k 0.7×	1.9k 1.4×	1.1k 1.3×	828 1.0×	429 0.6×	134	5.8k
Flaminio Cattabeni Italy	54	2.8k 1.2×	3.1k 2.3×	739 0.8×	1.7k 2.0×	629 0.9×	171	7.3k
Peter R. Dodd Australia	45	2.8k 1.2×	3.3k 2.4×	349 0.4×	1.6k 1.9×	619 0.9×	170	6.5k
Manfred Gerlach Germany	44	1.7k 0.7×	2.0k 1.5×	817 0.9×	1.1k 1.3×	2.6k 3.7×	174	6.7k
Konrad Talbot United States	31	2.2k 0.9×	2.0k 1.5×	394 0.4×	1.9k 2.3×	388 0.6×	54	5.6k

Countries citing papers authored by Robert E. Davis

Since Specialization

Citations

This map shows the geographic impact of Robert E. Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert E. Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert E. Davis more than expected).

Fields of papers citing papers by Robert E. Davis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert E. Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert E. Davis. The network helps show where Robert E. Davis may publish in the future.

Co-authorship network of co-authors of Robert E. Davis

This figure shows the co-authorship network connecting the top 25 collaborators of Robert E. Davis. A scholar is included among the top collaborators of Robert E. Davis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert E. Davis. Robert E. Davis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tohen, Mauricio, et al.. (2025). Long-term safety and tolerability of lumateperone 42 mg in patients with bipolar disorder: results from a 6-month open-label extension study. International Clinical Psychopharmacology. 41(2). 130–137. 1 indexed citations

Correll, Christoph U., Suresh Durgam, Hassan Lakkis, et al.. (2025). Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial. International Clinical Psychopharmacology. 41(2). 120–129. 1 indexed citations

Snyder, Gretchen L., Peng Li, Lei Zhang, et al.. (2024). Pharmacologic profile of ITI-333: a novel molecule for treatment of substance use disorders. Psychopharmacology. 241(7). 1477–1490. 1 indexed citations

Suppes, Trisha, Suresh Durgam, Richard Chen, et al.. (2023). Adjunctive lumateperone (ITI‐007) in the treatment of bipolar depression: Results from a randomized placebo‐controlled clinical trial. Bipolar Disorders. 25(6). 478–488. 16 indexed citations

McIntyre, Roger S., et al.. (2023). The efficacy of lumateperone on symptoms of depression in bipolar I and bipolar II disorder: Secondary and post hoc analyses. European Neuropsychopharmacology. 68. 78–88. 11 indexed citations

Dutheil, Sophie, Luke S. Watson, Robert E. Davis, & Gretchen L. Snyder. (2022). Lumateperone Normalizes Pathological Levels of Acute Inflammation through Important Pathways Known to Be Involved in Mood Regulation. Journal of Neuroscience. 43(5). 863–877. 14 indexed citations

Snyder, Gretchen L., Robert E. Davis, Amy E. Lin, et al.. (2022). The Effects of Acute and Chronic Selective Phosphodiesterase 1 Inhibition on Smooth Muscle Cell-Associated Aging Features. Frontiers in Pharmacology. 12. 818355–818355. 8 indexed citations

Calabrese, Joseph R., Suresh Durgam, Andrew Satlin, et al.. (2021). Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial. American Journal of Psychiatry. 178(12). 1098–1106. 65 indexed citations

Boer, Martine de, Dirk J. Duncker, René de Vries, et al.. (2021). Vascular Ageing Features Caused by Selective DNA Damage in Smooth Muscle Cell. Oxidative Medicine and Cellular Longevity. 2021(1). 2308317–2308317. 20 indexed citations

10.

Vanover, Kimberly E., Robert E. Davis, Yun Zhou, et al.. (2018). Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia. Neuropsychopharmacology. 44(3). 598–605. 58 indexed citations

11.

Snyder, Gretchen L., Jos Prickaerts, Lei Zhang, et al.. (2016). Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats. Psychopharmacology. 233(17). 3113–3124. 49 indexed citations

12.

Vanover, Kimberly E., Isaac Veinbergs, & Robert E. Davis. (2008). Antipsychotic-like behavioral effects and cognitive enhancement by a potent and selective muscarinic M₁ receptor agonist, AC-260584.. Behavioral Neuroscience. 122(3). 570–575. 28 indexed citations

13.

Tredici, Andria L. Del, K.E. Vanover, Sine Mandrup Bertozzi, et al.. (2008). Identification of novel selective V2 receptor non-peptide agonists. Biochemical Pharmacology. 76(9). 1134–1141. 5 indexed citations

14.

Vanover, Kimberly E., et al.. (2007). Pharmacokinetics, Tolerability, and Safety of ACP‐103 Following Single or Multiple Oral Dose Administration in Healthy Volunteers. The Journal of Clinical Pharmacology. 47(6). 704–714. 30 indexed citations

15.

Liu, Qingzhong, et al.. (2006). Regeneration of Hexaploid Plants of Sweet Cherry Dwarf Rootstock ‘Gisela 6’ from in vitro Leaves Treated with Colchicine. Acta Horticulturae Sinica. 35(2). 359–360. 1 indexed citations

16.

Herrnstadt, Corinna, Joanna L. Elson, Eoin Fahy, et al.. (2002). Reduced-Median-Network Analysis of Complete Mitochondrial DNA Coding-Region Sequences for the Major African, Asian, and European Haplogroups. The American Journal of Human Genetics. 70(5). 1152–1171. 414 indexed citations

17.

Soldner, Frank, Michael Weller, Sibylle Haid, et al.. (1999). MPP+ Inhibits Proliferation of PC12 Cells by a p21WAF1/Cip1-Dependent Pathway and Induces Cell Death in Cells Lacking p21WAF1/Cip1. Experimental Cell Research. 250(1). 75–85. 47 indexed citations

18.

Miller, Scott W., Patricia A. Trimmer, W. Davis Parker, & Robert E. Davis. (1996). Creation and Characterization of Mitochondrial DNA‐Depleted Cell Lines with “Neuronal‐Like” Properties. Journal of Neurochemistry. 67(5). 1897–1907. 107 indexed citations

19.

Swerdlow, Russell H., Janice K. Parks, Scott W. Miller, et al.. (1996). Origin and functional consequences of the complex I defect in Parkinson's disease. Annals of Neurology. 40(4). 663–671. 526 indexed citations breakdown →

20.

Emmerling, Mark R., V. Gregor, Roy D. Schwarz, et al.. (1994). PD 142676 (CI 1002), a novel anticholinesterase and muscarinic antagonist. Molecular Neurobiology. 9(1-3). 93–106. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact